Every material Form 8-K PTC Therapeutics filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PTC Therapeutics sold its retained interest in its Evrysdi royalty stream to Royalty Pharma Investments 2019 ICAV on December 29, 2025, for $240.0 million in upfront cash. The company also may receive three additional $20.0 million payments, each tied to royalty payments exceeding set thresholds in 2027, 2028 and 2029, and it no longer owns any part of the royalty.
Upfront cash consideration of $240.0 million paid to PTC Therapeutics on December 29, 2025
Three potential $20.0 million payments, conditioned on Assigned Royalty Payments above $347.0 million (2027), $363.0 million (2028) and $379.0 million (2029)
Retained interest sold was 9.5111% of the Royalty before the 2020 Assigned Royalty Cap is met and 16.6666% after; PTC now owns 0% of the Royalty
PTC Therapeutics reported third-quarter 2025 total revenue of $211.0 million, up from $196.8 million a year earlier, and net income of $15.9 million, compared with a net loss of $106.7 million in the same period of 2024. The company narrowed its full-year 2025 total revenue guidance to $750 million to $800 million and said the Sephience launch began in the US and Europe, though net product revenue for Translarna and Emflaza declined year over year.
Q3 2025 total revenue was $211.0 million, compared with $196.8 million in Q3 2024.
Q3 2025 net income was $15.9 million, or $0.20 per diluted share, versus a net loss of $106.7 million in Q3 2024.
Sephience generated $19.6 million in Q3 2025 global revenue, with 521 US patient start forms as of September 30, 2025.
Translarna net product revenue fell to $50.7 million from $72.3 million, and Emflaza fell to $35.2 million from $51.9 million.
On August 5, 2025, PTC Therapeutics entered a Rights Satisfaction Agreement under which former Censa Pharmaceuticals securityholders gave up their rights to payments based on sepiapterin net sales. The company paid about $225 million in cash at closing and may owe up to $500 million more in milestone payments. Other obligations under the 2020 Merger Agreement remain in effect.
At closing, PTC paid about $225.0 million in cash to participating former Censa securityholders, who held about 90% of Censa's equity.
Participants forfeited net sales payments of 8% on sales up to $250.0 million, 10% on sales from $250.0 million to $500.0 million, and 12% on sales above $500.0 million.
Additional milestone payments of about $90.0 million each, up to $500.0 million in total, are tied to aggregate net sales thresholds from $3.0 billion to $11.0 billion.
The agreement was signed and closed simultaneously, and the full text will be filed with the Form 10-Q for the quarter ending September 30, 2025.
PTC Therapeutics reported second-quarter 2025 total revenue of $178.9 million, down from $186.7 million a year earlier, while its net loss narrowed to $64.8 million from $99.2 million. The company also reaffirmed no prior guidance in this filing but gave full-year 2025 revenue guidance of $650 million to $800 million, and said Sephience received FDA approval on July 28, 2025.
Q2 2025 total revenue $178.9 million vs. $186.7 million in Q2 2024; net product revenue $118.3 million vs. $133.2 million
Q2 2025 net loss $64.8 million, or $0.83 per share, vs. net loss of $99.2 million, or $1.29 per share, in Q2 2024
Full-year 2025 revenue guidance of $650 million to $800 million
Agreed to buy the Sephience sales obligation owed to former Censa shareholders for a $225 million upfront payment; cash and marketable securities were $1,989.2 million at June 30, 2025
PTC Therapeutics reported first quarter 2025 results, with total revenue of $1,176.1 million and net income of $866.6 million, compared with a net loss of $91.6 million a year earlier. The results were driven by a $986.2 million license and collaboration payment from Novartis for PTC518, while net product and royalty revenue fell to $189.9 million from $208.8 million. The company narrowed its full-year 2025 revenue guidance to $650 million to $800 million.
Total revenue was $1,176.1 million, versus $210.1 million in the first quarter of 2024, including $986.2 million tied to the PTC518 license with Novartis, which closed in January 2025.
Net product and royalty revenue was $189.9 million, down from $208.8 million a year earlier.
Net income was $866.6 million, or $10.04 per diluted share, compared with a net loss of $91.6 million, or $1.20 per share, in the first quarter of 2024.
Full-year 2025 revenue guidance was narrowed to $650 million to $800 million; cash and marketable securities were $2,027.2 million as of March 31, 2025.
PTC Therapeutics reported fourth-quarter and full-year 2024 results. Revenue fell from a year earlier, while the net loss narrowed, with a $99.9 million gain on sale of a priority review voucher offsetting part of a $159.5 million intangible asset impairment. The company guided full-year 2025 total revenue to between $600 million and $800 million.
Q4 2024 total revenue was $213.2 million, versus $307.1 million in Q4 2023; full-year 2024 revenue was $806.8 million, versus $937.8 million in 2023.
Q4 2024 net loss was $65.9 million, or $0.85 per share, versus $155.8 million, or $2.06 per share, in Q4 2023.
Q4 2024 results include a $159.5 million intangible asset impairment and a $99.9 million gain on sale of a priority review voucher.
2025 guidance: total revenue of $600 million to $800 million; cash, cash equivalents and marketable securities were $1,139.7 million on December 31, 2024.
PTC Therapeutics reported preliminary, unaudited 2024 total revenue of approximately $814 million, which the company said exceeded its guidance, and gave 2025 total revenue guidance of $600 million to $800 million. The 2025 range sits below the 2024 preliminary figure, and the 2024 numbers remain subject to the year-end audit.
Unaudited 2024 total net revenue of approximately $814 million; net product revenue approximately $601 million
Translarna approximately $340 million and Emflaza approximately $207 million in unaudited 2024 net product revenue; Evrysdi royalty revenue approximately $211 million
2025 guidance: total revenue $600 million to $800 million; GAAP R&D and SG&A expense $805 million to $835 million
Results will be presented at the J.P. Morgan Healthcare Conference on January 13, 2025, after which the company enters a quiet period
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PTC Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →